Naggie S et al., 2022-10-25: ACTIV-6, the US decentralized platform trial, randomized 1591 outpatients to ivermectin 400 micrograms/kg daily for three days or placebo and found no improvement in time to sustained recovery.
Among outpatients with mild to moderate COVID-19, treatment with ivermectin, compared with placebo, did not significantly improve time to recovery.
Naggie S et al., 2022-10-25: ACTIV-6, the US decentralized platform trial, randomized 1591 outpatients to ivermectin 400 micrograms/kg daily for three days or placebo and found no improvement in time to sustained recovery. Decentralized, double-blind, randomized, placebo-controlled platform trial, N=1591 adults 30 and older with confirmed COVID-19 and 2+ symptoms for 7 days or less, United States, June 2021-February 2022; ivermectin 400 micrograms/kg (n=817) daily for 3 days vs placebo. Time to recovery 12 vs 13 days; hospitalizations or deaths 10 vs 9 (1.2% vs 1.2%; HR 1.1, 95% CrI 0.4-2.6). Disclosures: Dr Naggie reports NIH grants during the study plus grants from Gilead Sciences and AbbVie (declared in the paper). Funded by the US government (NIH/Operation Warp Speed per the trial record). NCT04885530. Study type: randomized trial.
